Physician profile
Mayank Lahoti
NPI 1255659868
$2,198.44
in general payments reported to CMS, 2019-2025
25 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $93.41 · 2021: $55.62 · 2022: $273 · 2023: $365 · 2024: $318 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.65 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $643.48 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.54 | 2019-2025 | Xifaxan, Akreos Ao Micro Incision Lens |
| Takeda Pharmaceuticals U.S.A., INC. | $169.62 | 2019-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $112.25 | 2019-2023 | Cimzia, Rebyota |
| Madrigal Pharmaceuticals | $90.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $88.66 | 2019-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $86.76 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $80.15 | 2019-2025 | |
| Celgene Corporation | $58.56 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $58.19 | 2023 | Stelara |
| Lilly USA, LLC | $56.77 | 2024-2025 | Omvoh |
| Genzyme Corporation | $55.05 | 2022-2025 | |
| Pfizer INC. | $47.32 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $41.13 | 2020-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $39.75 | 2025 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $34.27 | 2025 | Sucraid |
| Exact Sciences Corporation | $18.21 | 2025 | The Cologuard Plus Collection Kit |
| Sandoz INC. | $17.84 | 2023 | Hyrimoz |
| Ardelyx, INC. | $17.57 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $16.02 | 2024 | |
| Celltrion USA INC. | $15.99 | 2024 | Zymfentra |
| Mauna Kea Technologies, INC. | $15.83 | 2025 | |
| Fresenius Kabi USA, LLC | $14.77 | 2023 | Idacio |
| Alfasigma USA, INC. | $13.18 | 2020 | |
| Vivus LLC | $10.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayank Lahoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.